RET gene alterations are oncogenic drivers of several cancer types.1RET fusions are present in about 1% to 2% of patients with NSCLC.2–4 Selpercatinib is a first-in-class highly selective and potent RET kinase inhibitor with central nervous system activity. The gene discussed is RET; the disease is cancer.